NEWS

• Approval aligns with universal age recommendation for all eligible people six months and older to receive annual influenza vaccination 1
• Cell-based influenza vaccines are designed to produce an exact match to the World Health Organization (WHO)-selected influenza virus strains 2,3
• This approval reinforces the value of this innovative influenza vaccine technology as part of Seqirus’ mission to help protect as many eligible people as possible against influenza, especially in light of the ongoing COVID-19 pandemic

• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
• Company will utilize its combination of cell-based and adjuvanted influenza vaccine technologies, as well as its next-generation self-amplifying mRNA platform
• Multi-year contract with Biomedical Advanced Research and Development Authority (BARDA) builds on longstanding, successful public-private partnership to provide rapid vaccine manufacturing response in an influenza pandemic

• Appoints Roberta Duncan as new program lead to drive technology advancement
• Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza

Findings from a new observational safety study conducted in the U.S. found no unexpected adverse pregnancy outcomes in pregnant people who were vaccinated with the cell-based quadrivalent seasonal influenza vaccine during pregnancy.

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic.

Company announces the publication of new real-world evidence on effectiveness of the MF59® adjuvanted, trivalent influenza vaccine (aTIV).

This news release is intended for business and trade media only.